Radiopharmaceutical · Kills target cells, directed at carbonic anhydrase IX (CAIX) (CA9) · developed by Telix Pharmaceuticals Pty
177Lu-TLX250 is a radiopharmaceutical made of the girentuximab antibody carrying the lutetium-177 radioisotope via a tetraxetan chelator. The antibody targets carbonic anhydrase IX, and the drug is studied in clear cell renal cell carcinoma and other metastatic or recurrent renal cell cancers.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07870746 | Phase 2 | ccRCC | Not yet recruiting | TLX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
ccRCCClear Cell Renal Cell Cancer (ccRCC)Renal Cell Cancer MetastaticRenal Cell Cancer, RecurrentRenal Cell Carcinoma (Kidney Cancer)Renal Cell Carcinoma (RCC)
Updated Nov 8, 2026. Something wrong or missing? Report it on the TLX page.
See TLX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
TLX catalysts and pipeline →